RT Journal Article
T1 Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19.
A1 García-García, José A
A1 Pérez-Quintana, Marta
A1 Ramos-Giráldez, Consuelo
A1 Cebrián-González, Isabel
A1 Martín-Ponce, María L
A1 Del Valle-Villagrán, José
A1 Navarro-Puerto, María A
A1 Sánchez-Villegas, Jorge
A1 Gómez-Herreros, Rocío
A1 Manoja-Bustos, Isabel
A1 León-Martí, Daniel
A1 Serrano-Rodríguez, Lucía
A1 de Miguel-Albarreal, Alejandra
A1 Velasco-Romero, María J
A1 Mula-Falcón, Francisco
A1 Fernández-Pérez, Pilar
A1 Melguizo-Moya, Isabel
A1 Pérez-Quintana, María J
A1 Romero-Molina, Guillermo
A1 Vergara-López, Salvador
A1 Marenco-de la Fuente, José L
A1 Marín-Martín, Jorge
A1 Mira-Escarti, José A
K1 COVID-19
K1 anakinra
K1 baricitinib
K1 corticosteroids
K1 mortality
AB Immunomodulatory drugs have been used in patients with severe COVID-19. The objective of this study was to evaluate the effects of two different strategies, based either on an interleukin-1 inhibitor, anakinra, or on a JAK inhibitor, such as baricitinib, on the survival of patients hospitalized with COVID-19 pneumonia. Individuals admitted to two hospitals because of COVID-19 were included if they fulfilled the clinical, radiological, and laboratory criteria for moderate-to-severe disease. Patients were classified according to the first immunomodulatory drug prescribed: anakinra or baricitinib. All subjects were concomitantly treated with corticosteroids, in addition to standard care. The main outcomes were the need for invasive mechanical ventilation (IMV) and in-hospital death. Statistical analysis included propensity score matching and Cox regression model. The study subjects included 125 and 217 individuals in the anakinra and baricitinib groups, respectively. IMV was required in 13 (10.4%) and 10 (4.6%) patients, respectively (p = 0.039). During this period, 22 (17.6%) and 36 (16.6%) individuals died in both groups (p = 0.811). Older age, low functional status, high comorbidity, need for IMV, elevated lactate dehydrogenase, and use of a high flow of oxygen at initially were found to be associated with worse clinical outcomes. No differences according to the immunomodulatory therapy used were observed. For most of the deceased individuals, early interruption of anakinra or baricitinib had occurred at the time of their admission to the intensive care unit. Similar mortality is observed in patients treated with anakinra or baricitinib plus corticosteroids.
SN 2077-0383
YR 2021
FD 2021-09-06
LK http://hdl.handle.net/10668/18507
UL http://hdl.handle.net/10668/18507
LA en
DS RISalud
RD Apr 6, 2025